ClinicalTrials.gg
CompletedNCT03102905REPLIPOUpdated Jun 12, 2026

Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?

An observational study in HHV6, Exanthema and Hemopathy, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
37
Sex
All
01

Study summary

To look for the replication of HHV6 by PCR in the skin, in these patients with haemopathies presenting an exanthema. This will make it possible to evaluate the prevalence of the positivity of this PCR in the skin. Then the investigator can investigate whether there is an association between the positivity of HHV6 PCR in the blood and / or skin and the viral etiology of the exanthema. If this association exists, it will make it possible to improve the diagnosis in the context of the exanthema and thus to improve the therapeutic management of these patients.

02

Conditions studied

  • HHV6
  • Exanthema
  • Hemopathy

Browse trials for

03

In context

Exanthema

68 studies on the registry are indexed under Exanthema; 11 are open to participants now.

This study's enrollment of 37 is below the median of 71 across 18 observational studies indexed under Exanthema.

Browse Exanthema studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient hospitalized in the Clinical Hematology and Cellular Therapy department of the CHU Amiens-Picardie between 01/01/2011 and 31/01/2016

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Supported for any type of hemopathy.
  • Allograft, autografted or ungrafted haematopoietic stem cells
  • Having presented an exanthema during hospitalization, for which a cutaneous had been performed
  • Having had a blood test of the HHV6 virus by PCR at least within the previous 40 days or following the rash.
  • Age greater than or equal to 18 years
  • Patient informed of the protocol by post, not having refused within one month of sending the said courier.

Exclusion criteria

Exclusion Criteria:

  • Patient who refused the search.
  • Patient whose HHV6 PCR in the blood was carried out at a distance of more than 40 days from the skin .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
37 participants (actual)
Patient registry
No

Interventions

  • OtherMeasurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.

    To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.

06

What researchers measure

Primary outcomes

  1. Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.

    Time frame: 1 day

07

Study locations

1 site
  • CHU Amiens Picardie
    Amiens, Picardie 80054, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Sep 2018, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2017
First posted
Apr 6, 2017
StartActual
Dec 12, 2016
Primary completionActual
Sep 28, 2018
CompletionActual
Sep 28, 2018
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03102905
Responsible party
Sponsor
First posted
Apr 6, 2017
Start date
Dec 12, 2016
Primary completion
Sep 28, 2018
Completion
Sep 28, 2018
Last update
Jun 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion